Literature DB >> 30872813

Reversal of cardiac, vascular, and renal dysfunction by non-quinazoline α1-adrenolytics in DOCA-salt hypertensive rats: a comparison with prazosin, a quinazoline-based α1-adrenoceptor antagonist.

Monika Kubacka1, Monika Zadrożna2, Barbara Nowak2, Magdalena Kotańska3, Barbara Filipek3, Anna Maria Waszkielewicz4, Henryk Marona4, Szczepan Mogilski3.   

Abstract

We investigated the therapeutic effect of MH-76 and MH-79, which are non-quinazoline α1-adrenoceptor antagonists with an additional ability to stimulate the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP)/K + pathway, on deoxycorticosterone acetate (DOCA)-salt induced hypertension in rats. Prazosin was used as a reference compound, as quinazoline-based α1-adrenolytics may potentially exert unfavorable proapoptotic and necrotic effects. DOCA-salt hypertension was induced by DOCA (20 mg/kg s.c., twice weekly) administration plus 1% NaCl and 0.2% KCl solutions in drinking water for 12 weeks. The studied compounds MH-76, MH-79 (10 mg/kg i.p.) or prazosin (0.4 mg/kg i.p.) were administered to the DOCA-salt-treated rats, starting from the 6th week of DOCA-salt treatment and continuing for 6 weeks. This study showed that the administration of MH-79 and, to a lesser extent, MH-76 decreased elevated systolic blood pressure and heart rate, reduced heart and kidney hypertrophy, and reversed the histopathological alterations of the heart, kidney, and vessels in DOCA-salt hypertensive rats. MH-79 reversed endothelial dysfunction, which reduced inflammatory cell infiltration, arteriosclerotic alterations in renal and coronary arteries, and tubulointerstitial fibrosis. Prazosin showed a potent hemodynamic effect and reduced cardiac and renal fibrosis but exerted detrimental effects on blood vessels, potentiating fibroplasia of the media of the intrarenal artery and causing calcification of coronary arteries. Prazosin did not reverse endothelial dysfunction. Our results show the beneficial effect of non-quinazoline α1-adrenolytics on cardiac, vascular, and renal dysfunction in DOCA-salt hypertensive rats. Our findings also support the idea that targeting endothelial protection and endothelial integrity would yield beneficial effects against cardiac, blood vessel and renal injury related to hypertension.

Entities:  

Keywords:  DOCA-salt hypertensive rats; endothelial dysfunction; nitric oxide; α1-adrenoceptor antagonist

Mesh:

Substances:

Year:  2019        PMID: 30872813     DOI: 10.1038/s41440-019-0239-1

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  3 in total

1.  Models of cardiovascular disease: measurement of antihypertensive activity in the conscious rat (SHR, DOCA-salt, and Goldblatt hypertension models).

Authors:  Philippe Guillaume; Daniel Provost; Pamela Legrand; Michael Godes; Pierre Lacroix
Journal:  Curr Protoc Pharmacol       Date:  2009-03

2.  Synthesis, alpha-adrenoceptors affinity and alpha 1-adrenoceptor antagonistic properties of some 1,4-substituted piperazine derivatives.

Authors:  H Marona; M Kubacka; B Filipek; A Siwek; M Dybała; E Szneler; T Pociecha; A Gunia; A M Waszkielewicz
Journal:  Pharmazie       Date:  2011-10       Impact factor: 1.267

Review 3.  Therapeutic value of quinazoline-based compounds in prostate cancer.

Authors:  Johnathan Bilbro; Matthew Mart; Natasha Kyprianou
Journal:  Anticancer Res       Date:  2013-11       Impact factor: 2.480

  3 in total
  2 in total

1.  Sodium butyrate ameliorates deoxycorticosterone acetate/salt-induced hypertension and renal damage by inhibiting the MR/SGK1 pathway.

Authors:  Chunying Wu; Zhida Chen; Linlin Zhang; Yeyan Zhu; Mokan Deng; Cailin Huang; Yuting Liu; Qing Zhu; Lei Wang
Journal:  Hypertens Res       Date:  2020-09-09       Impact factor: 3.872

2.  MH-76, a Novel Non-Quinazoline α1-Adrenoceptor Antagonist, but Not Prazosin Reduces Inflammation and Improves Insulin Signaling in Adipose Tissue of Fructose-Fed Rats.

Authors:  Monika Kubacka; Szczepan Mogilski; Monika Zadrożna; Barbara Nowak; Małgorzata Szafarz; Bartosz Pomierny; Henryk Marona; Anna Waszkielewicz; Wojciech Jawień; Jacek Sapa; Marek Bednarski; Joanna Knutelska; Magdalena Kotańska
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.